US69012T3059
US69012T3059
Outlook Therapeutics, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 50/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±120.3% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.7x).
Beta (Market Relation)
0.67x
DefensiveVolatility (5Y p.a.)
120.3% p.a.
5-Year HorizonMax Drawdown (5Y)
-99.5%
5-Year HorizonSharpe Ratio
-0.50
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Volatility Expansion (3Y > 5Y) High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -55.2% |
| 3 Years | 134.9% | -98.5% | -0.39 | -50.4% |
| 5 Years | 120.3% | -99.5% | -0.5 | -58.2% |
| 10 Years | 123.8% | -100.0% | -0.43 | -50.4% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Elevated Short-Term Volatility: 3Y volatility (134.9%) is noticeably higher than the 5Y average (120.3%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (120.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -100.0% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
-
Audit Risk
-
Board Risk
-
Short Ratio
2.56